Effect of antacids on aspirin dissolution and bioavailability

Nayak, R. K.; Smyth, Robert D.; Poik, Andrew; Herczeg, T; Carter, Victoria; Visalli, Anthony J.; Reavey-Cantwell, Nelson H.

doi:10.1007/bf01059686

Cited by 7 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of its rapid conversion to salicylate, its concentrations in both the plasma and urine decline within a short period while that of salicylate increases and maintained for a long time thereby making the assessment of salicylate a good parameter for assessing aspirin bioavailability [5,6]. Many factors such as drug formulation, rate of gastric emptying, volume of blood, concurrent administration of other drugs, posture, exercise and pH of stomach content affect the rate and extent of absorption of the drug [7,8].…”

Section: Introductionmentioning

confidence: 99%

Comparative bioequivalence assessment of aspirin tablets marketed in Nigeria

Bamigbola¹,

Ibrahim²,

Attama³

et al. 2010

Int J Health Res

View full text Add to dashboard Cite

an online international journal allowing free unlimited access to abstract and full-text of published articles. The journal is devoted to the promotion of health sciences and related disciplines (including medicine, pharmacy, nursing, biotechnology, cell and molecular biology, and related engineering fields). It seeks particularly (but not exclusively) to encourage multidisciplinary research and collaboration among scientists, the industry and the healthcare professionals. It will also provide an international forum for the communication and evaluation of data, methods and findings in health sciences and related disciplines. The journal welcomes original research papers, reviews and case reports on current topics of special interest and relevance. All manuscripts will be subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication) will be published without delay. The maximum length of manuscripts should normally be 10,000 words (20 single-spaced typewritten pages) for review, 6,000 words for research articles, 3,000 for technical notes, case reports, commentaries and short communications. Submission of Manuscript:The International Journal of Health Research uses a journal management software to allow authors track the changes to their submission. All manuscripts must be in MS Word and in English and should be submitted online at http://www.ijhr.org. Authors who do not want to submit online or cannot submit online should send their manuscript by e-mail attachment (in single file) to the editorial office below. Submission of a manuscript is an indication that the content has not been published or under consideration for publication elsewhere. Authors may submit the names of expert reviewers or those they do not want to review their papers. Enquiries AbstractPurpose: In the last few years, aspirin has become a life saver against cardiovascular accidents. This investigation was carried out to determine possible bioequivalence between regular aspirin and soluble aspirin tablets marketed in Nigeria. Methods:The in vivo bioavailability profiles of three commercial brands of aspirin tablets and soluble aspirin tablets were assessed in eight healthy subjects. Pharmacokinetic parameters including amounts of aspirin excreted up to 24h (E 24h ), maximum excretion rate (dE/dt) max and time for maximum excretion rate (T max ) were compared for all the brands. Results: There was no significant difference (p > 0.05) in the maximum excretion rates among all the brands but the amount of soluble aspirin excreted up to 24 hours was a significantly different (p< 0.05) from one of the regular brands of aspirin. The soluble brand had significantly lower T max (p < 0.05) than all the three plain brands. There was no significant inter-subject variation among the subjects that participated in the study. Conclusion:Bioinequivalence exists between some regular aspirin and soluble aspirin marketed in Nigeria.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative bioequivalence assessment of aspirin tablets marketed in Nigeria

Bamigbola¹,

Ibrahim²,

Attama³

et al. 2010

Int J Health Res

View full text Add to dashboard Cite

show abstract

Estimation problem due to multiple solutions in pharmacokinetic curve fitting to two‐compartment model and its avoidance

Murata

Kohno

1989

Biopharm & Drug Disp

View full text Add to dashboard Cite

A size of error in observed data for fitting curves and an estimation problem due to multiple solutions in a two-compartment model were studied by using two different non-linear least-squares regression programs, SALS and NONLIN. It was found that bolus intravenous data have generally 5-10 per cent errors and oral data contain 10-25 per cent errors against the fitted data with respect to total 151 data sets of 11 different drugs. Parameters of five drugs reported in references were used to obtain simulated concentrations at the sampling times, and five different data sets containing 25 per cent normally distributed random errors as a coefficient of variation were generated using each data set of these simulated concentration. In the two-compartment model with tri-exponential equations, unreasonable estimates were occasionally observed, resulting in reversed relative values to the theoretical ones of L/M, L/N, M/N or Ka/alpha, which are analogous to the well-known flip-flop phenomenon in the one-compartment model, when number of parameters to be estimated is not less than five or errors of data exceed about 10 per cent. In an attempt to avoid such unreasonable values, initial estimates for curve fitting was successfully obtained by using a microcomputer program SIMPLEX based on a simplex method. On the basis of these results, some problems in curve fitting of plasma drug concentration data are discussed.

show abstract

Pharmacokinetic interactions between arbaprostil and aspirin in humans

Hsyu

Cox

Pullen

et al. 1989

Biopharm & Drug Disp

View full text Add to dashboard Cite

Arbaprostil is an orally active prostaglandin E2 analogue. It has been developed as a drug to treat ulcers induced by non-steroidal anti-inflammatory drugs. In this study, pharmacokinetic interactions between arbaprostil and aspirin were examined in humans after chronic doses of both drugs. Subjects received either arbaprostil (50 micrograms), aspirin (975 mg) or arbaprostil (50 micrograms) and aspirin (975 mg) four times a day for 6 days and one dose on 7th day. Blood and urine samples were collected after the last dose for 6 h. Pharmacokinetic parameters of arbaprostil, aspirin, and salicylate were determined. Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate). The pharmacokinetics of salicylate were not changed by arbaprostil, nor were the pharmacokinetics of arbaprostil affected by aspirin. Coadministration of these two drugs did not appear to potentiate the side-effects of either drug. The results suggest that arbaprostil and aspirin may be administered together without clinically significant changes in pharmacokinetics or adverse side-effects.

show abstract

Effect of antacids on aspirin dissolution and bioavailability

Cited by 7 publications

References 18 publications

Comparative bioequivalence assessment of aspirin tablets marketed in Nigeria

Comparative bioequivalence assessment of aspirin tablets marketed in Nigeria

Estimation problem due to multiple solutions in pharmacokinetic curve fitting to two‐compartment model and its avoidance

Pharmacokinetic interactions between arbaprostil and aspirin in humans

Contact Info

Product

Resources

About